Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?

Melanoma Research

Volumn 10, Issue 1, 2000, Pages 47-54

  Wu, Z Y ^a   Smithers, B M ^a   Anderson, C ^b   Roberts, M S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Drug monitoring; Isolated limb perfusion; Microdialysis; Tissue drug concentration

Indexed keywords

MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIALYSATE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMB PERFUSION; MELANOMA; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT;

EID: 0034009484     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200002000-00007     Document Type: Article

References (35)

1. 1. Blochl-Daum B, Muller M, Meisinger V, Eichler HG, Fassolt A, Pehamberger B. Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer 1996; 73: 920-924.
2. 2. Los G, Robbins TK, Barton RM, Hanchett CA, Heath DD, Vicario D, Howell SB. Quantitation of tumour platinum content in patients receiving superselective arterial infusion of high dose cisplatinin in advanced head and neck cancers: a preliminary report. Proc Am Soc Clin Oncol 1993; 12: 284.
3. 3. Vaden SL, Williams PL, Page RL, Riviere JE. Effect of tumour presence on cisplatin and carboplatin: disposition in the isolated, perfused tumour and skin flap. Cancer Chemother Pharmacol 1991; 32: 31-38.
4. 4. Scott RN, Blackie R, Kerr DJ, Hughes J, Burnside G, Mackie RM, Byrne DS, McKay AJ. Melphalan concentration and distribution in the tissues of tumourbearing limbs treated by isolated limb perfusion. Eur J Cancer 1992; 18A: 1811-1813.
5. 5. Klaase JM. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the low limb. Br J Cancer 1994; 70: 151-153.
6. 6. Jain RK. Barriers to drug delivery in solid tumours. Sci Am 1994; 7: 58-65.
7. 7. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumor pharmacokinetics of fluorouracil with clinical response. Lancet 1994; 343: 1184-1187.
8. 8. Muller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blochl-Daum B. 5-Fluorouracil kinetics in the interstitial tumour space: clinical response in breast cancer patients. Cancer Res 1997; 57: 2598-2601.
9. 9. Lonnroth P, Jansson PA, Smith U. Measurements by microdialysis of free tissue concentrations of propranolol. J Chromatogr 1991; 568: 419-425.
10. 10. Stahle L. Drug distribution studies with microdialysis III. Extracellular concentrations of caffeine in adipose tissue in man. Life Sci 1991; 49: 1853-1858.
11. 11. Scheyer RD, During MJ, Spencer DD, Cramer JA, Matton RH. Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. Neuroscience 1994; 44: 1469-1472.
12. 12. Muller M, Schmid R, Georgopoulos A, Buxbaum A, Wasicek C, Eichler HG. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 1995; 57: 371-380.
13. 13. Delgado JMR, DeFeudis FV, Roth RH, Ryugo DK, Mitruka BM. Dialyttrode for long term intracerebral perfusion in awake monkeys. Arch Int Pharmacodynamie 1972; 198: 9-21.
14. 14. Arner P, Kriegholm E, Engfeldt P. In situ studies of catecholamine-induced lipolysis in human adipose tissue with microdialysis. J Pharmacol Exp Ther 1990; 254: 284-288.
15. 15. Cross SE, Anderson C, Thompson MJ, Roberts MS. Is there tissue penetration after application of topical salicylate formulations? Lancet 1997; 350: 636-637.
16. 16. Palsmeier RK, Lunte CE. Microdialysis sampling in tumour and muscle: study of the disposition of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (SR4233). Life Sci 1994; 55: 815-825.
17. 17. Scott DO, Lunte CE. In vivo microdialysis sampling in the bile, blood and liver of rats to study the disposition of phenol. Pharmacol Res 1993; 10: 335-342.
18. 18. Monson JRT. Malignant melanoma: a plague of our times. Br J Surg 1989; 76: 997-998.
19. 19. Markowitz JS. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991; 126: 703-707.
20. 20. Thompson JF. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14(3): 238-247.
21. 21. Wu ZY, Rivory LP, Roberts MS. Physiological pharmacokinetics of solutes in the isolated perfused rat hindlimb: characterization of the physiology with changing perfusate flow, protein content, and temperature using statistical moment analysis. J Pharmacokin Biopharmacol 1993; 21: 653-688.
22. 22. Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp Ther 1997; 282: 1131-1138.
23. 23. Wu ZY, Smithers BM, Roberts MS. Melphalan dosing-regimens for management of recurrent melanoma by isolated limb perfusions: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. Melanoma Res 1997; 7: 252-264.
24. 24. Wu ZY, Smithers BM, Roberts MS. The effects of perfusion conditions on melphalan distribution in isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer 1997; 75(8): 1160-1166.
25. 25. Ungerstedt U. Microdialysis - principles and applications for studies in animals and man. J Intern Med 1991; 230: 365-373.
26. 26. Wu ZY, Thompson MJ, Addison RS, Smithers BM, Roberts MS. High performance liquid chromatographic assay for the measurement of melphalan and hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusion. J Chromatogr B 1995; 673: 267-279.
27. 27. Ekstrom PO, Andersen A, Warren DJ, Giercksky KE, Slordal L. Evaluation of methotrexate tissue exposure by in situ microdialysis in a rat model. Cancer Chemother Pharmacol 1994; 34: 297.
28. 28. Hartley JW, Fletcher WS. Improved survival of patients with stage II melanoma of the extremity using hyperthermic isolation perfusion with 1-phenylalanine mustard. J Surg Oncol 1987; 36(3): 170-174.
29. 29. Stehlin JS. Heat as an adjuvant in the treatment of advanced melanoma. An immune stimulant? Houston Med J 1988; 4: 61-64.
30. 30. Hafstrom L, Rudenstan CM, Blomquist E, Ingoar C, Jonsson PE, Lagerlof B, Lindhol MC, Ringborg U, Westman G, Ostrup L. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol 1991; 9: 2091-2094.
31. 31. Kroon BBR, Klaase JM, Vn Geel AN, Eggermont AMM. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat 1992; 4: 223-226.
32. 32. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma-effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 6: 227-233.
33. 33. Thompson JF, Kam PCA, Ramzan I, Yau DF. Clinical pharmacokinetics of melphalan in isolated limb perfusion: compartmental modelling and moment analysis. Reg Cancer Treat 1995; 8: 83-87.
34. 34. Ekstrom PO, Andersen A, Warren DJ, Giercksky KE, Slordal L. Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model. Cancer Chemother Pharmacol 1995; 36: 283-289.
35. 35. Weiss M, Koester A, Wu ZY, Roberts MS. Distribution kinetics of diazepam, lidocaine and antipyrine in the isolated perfused rat hindlimb. Pharmacol Res 1997; 14: 1640-1643.